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Alport syndrome is a collagen type IV disease caused by
mutations in the COL4A5 gene with the X-linked form being
most prevalent. The resultant a5(IV) collagen chain is a
component of the glomerular and skin basement membranes
(SBMs). Immunofluorescent determination of the a5(IV) chain
in skin biopsies is the procedure of choice to identify
patients. In 30% of patients, however, the mutant protein is
still found in the SBM resulting in a normal staining pattern.
In order to minimize or eliminate false results, we compared
the distribution of the a2(IV) chain (another SBM component)
and the a5(IV) chain by standard double label
immunofluorescence (IF) and by confocal laser scanning
microcopy. The study was performed on 55 skin biopsies of
patients suspected of Alports and five normal control
specimens. In normal skin, IF showed the classical linear
pattern for both collagens along the basement membrane.
Additionally, decreased a5(IV) was found in the bottom of the
dermal papillary basement membrane. Confocal analysis
confirmed the results and show a5(IV) focal interruptions. In
suspected patients, both techniques showed the same rate of
abnormal a5(IV) expression: segmental in women and absent
in men. Our results show a physiological variation of a5(IV)
location with focal interruptions and decreased expression in
the bottom of the dermal basement membrane. Comparison
of a5(IV) with a2(IV) expression is simple and eliminates
technical artifacts.
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Alport syndrome (AS) is a type IV collagen disease.1 The
X-linked form of the AS is the most prevalent transmission
(85%), and is caused by mutations in COL4A5.2 Approxi-
mately, 15% of AS are caused by COL4A3 and COL4A4
mutations with an autosomal recessive or rarely dominant
pattern of inheritance.1,3,4 The a1 chain of collagen IV (IV),
a2(IV), a3(IV), a4(IV), and a5(IV) chains are components
of glomerular basement membrane.5 Skin basement mem-
brane (SBM) is composed of a1(IV), a2(IV), a5(IV), and
a6(IV), but not a3(IV) and a4(IV), rendering skin analysis
uninformative in autosomal AS. In most X-linked AS
patients, immunofluorescence (IF) analysis of the skin
biopsy shows lack of a5(IV) chain, making skin biopsy a
procedure of choice to identified X-linked AS patients.6–9
However, in 30–40% of patients with proven COL4A5
mutations, immunohistochemical staining for a5(IV) is
normal, suggesting that the mutation had not prevented
incorporation of the a5(IV) chain into glomerular and
SBM.10–13
Recently, it was suggested that confocal laser staining
microscopy (CLSM) skin analysis is more precise, allowing
identification of an irregular distribution rather than the
absence of the a5(IV) chain in male and female cases with
COL4A5 mutations.14
The aim of the study was to more precisely differentiate
between physiological and abnormal distribution of a5(IV)
chain in SBM of AS patients. For this purpose, we used dual
staining for a2(IV), which is not affected in AS, and a5(IV).
Furthermore, we studied all biopsies with standard and
CLSM.
RESULTS
In normal skin, standard double direct IF showed an
uninterrupted linear pattern of a2(IV) and a5(IV) along
the SBM (Figure 1a–c). Unexpectedly, we observed decreased
or absence of a5(IV) expression in the bottom of dermal
papillary BM, contrary to a2(IV), which was always strongly
expressed (Figure 1d–f).
CLSM gave the same results than standard IF (not shown).
In addition, the high resolution image by CSLM revealed that
a5(IV) could be focally absent in normal skin (two out of
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Figure 1 | Expression of a5(IV) in normal skin. (a–c) Normal skin (20 /0.50 standard dual immunostaining). Expression of a5(IV) in green
(a) and a2(IV) in red (b). (c) Merge Bar 10 mm. (d–f) Normal skin in papillary zone (10 standard dual immunostaining). (d) a2(IV) in red was
expressed along EBM in the upper (double arrow) and the bottom (arrow) of the dermal papillary basement membrane, and strongly on
capillary wall. (e) a5(IV) in green was expressed along EBM but decreased in the bottom of dermal papillary basement membrane (arrow)
(f) merge. (g–m) Focal interruption of a5(IV) (10CLSM). (g) Continuous positive staining of a2(IV), (h) but focal absence of a5(IV) in normal
skin (red lines), (i) merge. (j) Z projection of a2(IV), (k) projection of a5(IV), and (l) merge of Z projection. (m) Quantitative analysis using
imaging analysis software of an LSM510 system: focal negative segment with a5(IV) (green curve) is included between 12 and 17 mm distance
(red and blue lines) compared with a2(IV) (red curve).
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five) in segments o5mm long, contrary to a2(IV), which
remained positive (Figure 1g–i). These small foci of negative
staining were even more obvious when quantitative analysis
of fluorescence was performed (Figure 1j–m).
In male patients suspected of having X-linked AS, 11/20
biopsies (55%) showed a2 and a5(IV) normal expression
with standard IF. Using CSLM, no defect potentially missed
by double standard IF could be observed in these 11 patients.
In nine cases, a5(IV) was totally absent (Figure 2a), whereas,
the a2(IV) staining was normal (Figure 2b), with both
methods.
Segmental a5(IV) distribution was never observed in any
of the male patients, even with CLSM.
In female patients, 18/ 35 biopsies (51%) showed normal
expression of both chains with standard IF. Again, CSLM did
not identify abnormal staining in these18 female patients.
Sixteen biopsies showed a segmental a5(IV) (Figure 2c and d)
expression with a normal a2(IV) staining. Both standard IF
and CSLM disclosed the same pattern.
In one case, a5(IV) was totally absent with normal a2(IV)
distribution using both standard IF and CSLM.
In addition, among the 45 patients with continuous
(11 male subjects) or mosaic (34 female subjects) positivity
of a5(IV), CSLM revealed that in 7/45, a5(IV) was clearly
absent in small foci (o5mm long) along the SBM, contrary
to a2(IV), which was always strongly expressed. This pattern
was similar to that observed in normal skin (cf above).
In two cases, direct comparison of a5(IV) with a2(IV)
(inner control) revealed technical artifact. In those cases, the
two chains were negative because of the absence of antibodies
penetration on tissue sample (folds in the skin, Figure 3a–d or
air bubble Figure 3e–g).
When skin section was not perpendicular to SBM, we
observed a coarsely granular distribution of a5(IV), which
corresponds to a decreased signal with both methods
(Figure 3h). A similar decreased signal was observed with
a2(IV) (Figure 3i), excluding an abnormal expression of
a5(IV).
DISCUSSION
It was recently described that CSLM analysis of skin biopsies
could provide a more sensitive approach to diagnose AS
when normal a5(IV) staining is observed by conventional IF,
eliminating ‘false-negative’ results.14 The aim of the study was
to compare the two methods, but not to appreciate the
impact of each method in term of sensibility and specificity.
For this reason, we included all the biopsy received for
‘suspected AS patients’ and not only biopsy of patients with
unequivocal clinical criteria of AS.
We applied standard IF and confocal analysis to double
direct IF in skin biopsies with a solution containing
antibodies against a5(IV) and a2(IV) chains (Figure 1).
The most important finding we observed with both methods
was a decreased or a disappearance of a5(IV), but not a2(IV),
along the bottom of dermal papillary BM in normal skin.
This physiological variation of a5(IV) expression is described
for the first time and could be related to local BM
specialization, as it was suggested for hair growth cycle.15
Thus, analysis of Alport female skin biopsies has to be
interpreted with caution. Abnormal expression of a5(IV) can
be ascertained only when the negative zone is distant from
the bottom of dermal papillary BM and compared to a2(IV).
In male patients, the expression of a5(IV) was normal or
totally absent, and segmental expression was never found,
even with CLSM.
In addition, we noted focal interruptions of a5(IV)
(o5mm long, quantified by the standard imaging analysis
software of an LSM 510 system) in both several control and
AS skin biopsies, without a2(IV) abnormality, excluding a
technical artifact. We, thus, interpret this pattern as a
physiological variation of a5(IV) distribution contrary to
Muda et al.14
Conventional double IF using combined a5(IV) and
a2(IV) antibodies is fast and simple: (1) no antigen
demasking by urea denaturation is needed, (2) only one
section is necessary, (3) direct comparison of a5(IV) with
a2(IV) (inner control) avoid misinterpretation related to
technical artifact, (4) in our hands, CSLM results were
identical to double IF and did not ascertain the existence of
‘false-negative results’ obtained with conventional IF.
In conclusion, skin biopsy is now the first choice in
diagnosing AS. When excluding technical artefacts and
physiological variations described herein, it is absolutely
specific both for AS and for the X-linked mode of
inheritance. However, it remains uninformative in a sub-
stantial proportion of patients when normal expression of
a5(IV) is observed. Future developments in DNA analysis




Figure 2 | Expression of a5(IV) in the skin of patients meeting
criteria for Alport. Male patient with AS (10 standard dual
immunostaining): (a) absence of a5(IV) and (b) normal expression of
a2(IV). Female patient with AS (standard dual immunostaining):
(c) segmental expression of a5(IV) (10 0.50) (d, arrow) especially in
the upper part of the papillary dermis BM (20 /0.50).
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As skin expression of a5(IV) is one of the tools available
for genetic counseling, misinterpretation could have disas-
trous consequences. The use of double standard IF described
herein by trained observers should allow more confident
interpretation in routine examination.
MATERIALS AND METHODS
We have studied all the skin biopsies addressed to the Department of
Pathology during 1 year from 55 patients (35 women and 20 men)
suspected of having X-linked AS, based on classical clinical criteria:
family history of hematuria with or without progression to renal
failure, progressive sensorineural hearing loss; biopsies from five
patients investigated for systemic lupus erythematosus served as
controls.
Immunohistochemical staining was performed on frozen sec-
tions (3mm) with a commercially available combination of two
monoclonal antibodies staining a5(IV) green (fluorescein isothio-
cyanate; H53 rat IgG2a/kappa and B51 rat IgG2a) and a2(IV) red
(texas red; H25 rat IgG1/kappa) (Shigei medical Research Institute:
CFT-45325).
The expression of the epidermal basement membrane a5(IV)
chain was detected using a direct immunofluorescence method. The
sections were air-dried for 30 min, incubated with monoclonal
antibodies during 1 h.
The slides were examined with a LEICA DMLB 100 microscope
equipped with epifluorescence illumination optics and then with an
LSM Pascal confocal laser scanning microscope. The fluorescence
intensity of the selected area was quantitatively analyzed using the









Figure 3 | Technical pitfalls in analysis of a5(IV) staining in the skin. (a–d) Folds in the skin (10CLSM): apparent focal absence
of staining for both (a) a5(IV), (b) a2(IV) and (d) merge along the basement membrane when a folding occurs preventing antibodies
penetration (white dotted line c). (e–g) Air bubble (10 standard dual immunostaining): segmental absence (arrow) of staining (absence of
antibodies penetration) with both a5(IV) (e, green) and a2(IV) (f, red) antibodies; (g) merge. (h, i) Transversal section of basement membrane
(10 standard dual immunostaining): (h) a5(IV) expression appeared decreased because staining was scattered (arrow) when the plane of
section was not perpendicular to the BM. The same pattern (i) was observed with the a2(IV).
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